We demonstrate MTHFD2 inhibitors being well tolerated and more efficient than standard of care in AML in-vivo models, and provide evidence of strong synergy with ATR inhibitors and dUTPase inhibitors that may improve current anticancer treatments. The gene discussed is MTHFD2; the disease is acute myeloid leukemia.